KLH-2109

DRUG7 trials

Sponsors

Kissei Pharmaceutical Co., Ltd.

Conditions

EndometriosisUterine Fibroids (MeSH Heading: Leiomyoma)

Phase 2

A Randomized Open Label Study of KLH-2109 in Patients With Endometriosis(1)

CompletedNCT01395940

Kissei Pharmaceutical Co., Ltd.Endometriosis

Target: 20Updated: 2013-10-30

A Randomized, Placebo-controlled, Double-blind Study of KLH-2109 in Patients With Endometriosis (2)

CompletedNCT01533532

Kissei Pharmaceutical Co., Ltd.Endometriosis

Target: 100Updated: 2014-05-30

A Phase II Randomized Open Label Study of KLH-2109 in Patients With Endometriosis

CompletedNCT01629420

Kissei Pharmaceutical Co., Ltd.Endometriosis

Target: 20Updated: 2014-05-30

Late Phase II Clinical Study of KLH-2109 in Patients With Endometriosis

CompletedNCT02778919

Kissei Pharmaceutical Co., Ltd.Endometriosis

Start: 2016-05-09End: 2018-03-23Updated: 2019-06-04

Phase 3

A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia

CompletedNCT05440383

Kissei Pharmaceutical Co., Ltd.Uterine Fibroids (MeSH Heading: Leiomyoma)

Start: 2022-10-11End: 2024-08-21Updated: 2025-03-14

A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain

CompletedNCT05445167

Kissei Pharmaceutical Co., Ltd.Uterine Fibroids (MeSH Heading: Leiomyoma)

Start: 2022-10-11End: 2024-02-16Updated: 2025-11-25

A Clinical Study of KLH-2109 in Patients With Endometriosis

Active, not recruitingNCT07015268

Kissei Pharmaceutical Co., Ltd.Endometriosis

Start: 2025-06-09End: 2027-11-01Target: 288Updated: 2026-03-02

Related Papers

Linzagolix versus leuprorelin in Japanese women with uterine leiomyomas: a phase 3, randomized, active-controlled, non-inferiority trial.

2026-07-06